Abstract
摘要
相似文献
1
[The determination of heparin].
Ann Biol Clin (Paris). 1982;40(6):645-50.
2
The inhibition of the anticoagulant activity of heparin by platelets, brain phospholipids, and tissue factor.
Br J Haematol. 1984 Jun;57(2):229-38.
3
Monitoring of heparin treatment. Comparison of thrombin time, activated partial thromboplastin time, and plasma heparin concentration, and analysis of the behavior of antithrombin III.
Am J Clin Pathol. 1980 Jul;74(1):68-73. doi: 10.1093/ajcp/74.1.68.
4
Identification of two distinct heparin cofactors in human plasma. II. Inhibition of thrombin and activated factor X.
Thromb Res. 1974 Mar;4(3):463-77. doi: 10.1016/0049-3848(74)90081-4.
5
[Laboratory controls of heparin therapy with thrombin time, partial thromboplastin time and activated recalcification time].
Z Gesamte Inn Med. 1989 Apr 15;44(8):235-40.
6
Validity of serine protease inhibition tests in the evaluation and monitoring of the effect of heparin and its fractions.
Semin Thromb Hemost. 1985 Apr;11(2):112-20. doi: 10.1055/s-2007-1004367.
7
Practical considerations on the measurement of low molecular weight heparin anti-Xa activity.
Semin Thromb Hemost. 1985 Apr;11(2):108-11. doi: 10.1055/s-2007-1004366.
8
Molecular weight of heparin versus biologic activity. Some additional considerations.
Semin Thromb Hemost. 1985 Jan;11(1):29-33. doi: 10.1055/s-2007-1004355.
9
Preliminary biochemical and pharmacologic studies on a chemically synthesized pentasaccharide.
Semin Thromb Hemost. 1985 Apr;11(2):89-99. doi: 10.1055/s-2007-1004364.
10
Effects of heparin oligosaccharides with high affinity for antithrombin III in experimental venous thrombosis.
Thromb Haemost. 1982 Jun 28;47(3):244-8.
Zotero 插件